General Announcement::Glenmark receives ANDA approval for Theophylline Extended Release Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
04-Jun-2021 13:42:46
Status
New
Announcement Sub Title
Glenmark receives ANDA approval for Theophylline Extended Release Tablets
Announcement Reference
SG210604OTHR2FYN
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
04/06/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended Release Tablets, 300 mg and 450 mg

Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg

Attachments

SGX_PR_04062021.pdf
Total size =906K